Alnylam Pharmaceuticals, Inc. (ALNY) on Decifer

Decifer ranks ALNY number 66 of 269 tracked names on durable business quality.

Why it ranks here

• Sales are growing about 65% a year, faster than 92 in 100 companies we measure.
• It keeps about 13 cents of every sales dollar as cash, safer than 72 in 100 companies we measure.
• It earns about 14% a year on the money put into the business, better than 72 in 100 companies we measure.
• It costs about 6 times its yearly sales; the middle of its industry is 9. Cheaper than 76 in 100 companies we measure, against their own industries.

The current read

The evidence on ALNY lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full ALNY research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.